Staged by the presence of metastases at diagnosis.
The Osteosarcoma — Toronto Stage is a oncology scoring tool used in paediatric practice. Staged by the presence of metastases at diagnosis. It scores 1 criteria and interprets the total across 2 bands, so the number always arrives with the severity it implies rather than on its own. In PediAid each criterion is shown as a labelled option with the weight it carries, so the total can be checked rather than taken on trust.
1. They are Disease extent at diagnosis.
The total is interpreted as: 1 stage or more - Stage I - localised: localised osteosarcoma - approximately 60-70% long-term survival with neoadjuvant chemotherapy, limb-salvage surgery and adjuvant chemotherapy; 2 stage or more - Stage II - metastatic: metastatic osteosarcoma - approximately 20-30% survival. Aggressive chemotherapy plus resection of all resectable metastases.
No. It is a structured way to record and communicate severity. A clinician concerned about a child should act on that concern regardless of the total.
Histological necrosis ≥90% after neoadjuvant chemotherapy is a favourable prognostic factor.
Yes. Score definitions are bundled with the PediAid app, so the score computes without a connection.